Exact Mass: 271.96981339999996
Exact Mass Matches: 271.96981339999996
Found 250 metabolites which its exact mass value is equals to given mass value 271.96981339999996
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
(Z)-4-(2-Hydroxy-5-sulfonatophenyl)-2-oxo-3-butenoate
2,4,6-Trichloro-4-biphenylol
D004785 - Environmental Pollutants > D011078 - Polychlorinated Biphenyls
6,7-Dichloro-l-tryptophan
A non-proteinogenic L-alpha-amino acid that is L-tryptophan in which the hydrogens at positions 6 and 7 on the indole ring have been replaced by chlorines.
Zoledronate
Zoledronate (zoledronic acid, marketed by Novartis under the trade names Zometa and Reclast) is a bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases. An annual dose of Zoledronate may also prevent recurring fractures in patients with a previous hip fracture. Zoledronate is a single 5 mg infusion for the treatment of Pagets disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis. M - Musculo-skeletal system > M05 - Drugs for treatment of bone diseases > M05B - Drugs affecting bone structure and mineralization > M05BA - Bisphosphonates D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates
Hexose monophosphate
2,5-Dichloro-N-(Pyridin-3-Yl)thiophene-3-Carboxamide
(5S,6R)-5,6-dichloro-2-dichloromethyl-6-methyl-octa-1,3t,7-triene
4-bromo-6,8-dihydroxy-3-methylisochroman-1-one|4-bromo-6-hydroxymellein
Zoledronic acid
M - Musculo-skeletal system > M05 - Drugs for treatment of bone diseases > M05B - Drugs affecting bone structure and mineralization > M05BA - Bisphosphonates D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates
Zoledronate
M - Musculo-skeletal system > M05 - Drugs for treatment of bone diseases > M05B - Drugs affecting bone structure and mineralization > M05BA - Bisphosphonates D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates
2-Bromo-1-(chloromethyl)-4-(trifluoromethyl)benzene
4,5-dichloro-2-(2-fluorobenzyl)pyridazine-3(2h)-one
C11H7Cl2FN2O (271.99194439999997)
2-Propenoic acid,3-(3-bromo-4-hydroxy-5-methoxyphenyl)-
4-CHLORO-2-CHLOROMETHYL-5,6,7,8-TETRAHYDRO-BENZO[4,5]THIENO[2,3-D]PYRIMIDINE
C11H10Cl2N2S (271.99417200000005)
N-(2-Bromo-4-methyl-5-nitrophenyl)acetamide
C9H9BrN2O3 (271.97965039999997)
N-(4-Bromo-5-methyl-6-nitrophenyl)acetamide
C9H9BrN2O3 (271.97965039999997)
8-bromo-6-chloro-2h-chromene-3-carbaldehyde
C10H6BrClO2 (271.92396659999997)
3-bromo-N,N-dimethyl-5-nitrobenzamide
C9H9BrN2O3 (271.97965039999997)
Z-2-(2,3-Dichlorophenyl)methylene-3-oxobutanoic acid methyleater
C12H10Cl2O3 (272.00069700000006)
(7-BROMO-2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)(2-METHOXYPHENYL)METHANONE
(6-BROMO-2-PYRIDINYL)-CARBAMICACID,1,1-DIMETHYLETHYLESTER
(3-Bromo-5-(ethoxycarbonyl)phenyl)boronic acid
C9H10BBrO4 (271.98554700000005)
2-bromo-N-methyl-N-(4-nitrophenyl)acetamide
C9H9BrN2O3 (271.97965039999997)
4-Bromo-2,3,5,6-tetrafluorophenylboronic acid
C6H2BBrF4O2 (271.92673299999996)
1-(CHLOROMETHYL)-4-(METHYLSULFONYL)-2-(TRIFLUOROMETHYL)BENZENE
N-(2-(BROMOMETHYL)-5-NITROPHENYL)ACETAMIDE
C9H9BrN2O3 (271.97965039999997)
trisodium hydrogen (1-hydroxyethylidene)bisphosphonate
9-bromo-2-chloro-7-methylpyrido[1,2-a]pyrimidin-4-one
(1S,4S)-2-methyl-2,5-diazabicyclo[2.2.1]heptane dihydrobromide
1,3-Butanedione,1-benzo[b]thien-3-yl-4,4,4-trifluoro-
4-Chloro-2-(chloromethyl)-6,7-dimethoxyquinazoline
4-phenyl-5-(trifluoromethyl)-2-thiophenecarboxylic acid
2,3,5,6-Tetrachloro-1,4-benzenedimethanamine
C8H8Cl4N2 (271.94415680000003)
7-bromo-2-(chloromethyl)pyrido[1,2-a]pyrimidin-4-one
Methyl 2-(2,3-dichlorobenzylidine)acetoacetate
C12H10Cl2O3 (272.00069700000006)
(2-BROMO-PYRIDIN-3-YL)-CARBAMIC ACID TERT-BUTYL ESTER
(5-BROMO-2-METHOXY-PHENYL)-ACETIC ACID ETHYL ESTER
3-BROMO-2-(CHLOROMETHYL)-4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE
3-[(5-Bromo-pyridine-3-carbonyl)-amino]-propionic acid
C9H9BrN2O3 (271.97965039999997)
1-(Bromomethyl)-3-chloro-5-(trifluoromethyl)benzene
2-(2-HYDROXYETHYLAMINO)-N-(3-BROMOPHENYL)ACETAMIDE
5-(3-bromophenyl)-3-(chloromethyl)-1,2,4-oxadiazole
5-[(4-CHLOROPHENYL)SULFANYL]-1,2,3-THIADIAZOLE-4-CARBOXYLIC ACID
3-(4-Bromophenyl)-5-(chloromethyl)-1,2,4-oxadiazole
2H-Pyrido[1,2-a]-1,3,5-triazine-2,4(3H)-dithione,3-(2-pyridinyl)-
2-Bromo-1-(5-chloro-1-benzofuran-2-yl)ethanone
C10H6BrClO2 (271.92396659999997)
5-(4-bromophenyl)-3-(chloromethyl)-1,2,4-oxadiazole
7-BROMO-6-FLUORO-3,3-DIMETHYL-3,4-DIHYDROQUINOXALIN-2(1H)-ONE
C10H10BrFN2O (271.99604819999996)
6,8-DICHLORO-2H-CHROMENE-3-CARBOXYLIC ACID ETHYL ESTER
C12H10Cl2O3 (272.00069700000006)
(1S,4S)-2-Methyl-2,5-diazabicyclo[2.2.1]heptanedihydrobromide
2,3-diamino-5-bromo-6-(trifluoromethyl)pyrimidin-4-one
5-BROMO-2-(CYCLOHEXYLTHIO)PYRIMIDINE
C10H13BrN2S (271.99827580000004)
N-(3,4-Dichlorophenyl)-2-oxopyrrolidine-1-carboxamide
(2S)-2-azaniumyl-3-(6,7-dichloro-1H-indol-3-yl)propanoate
(2R,3R,4S,5R)-2-arsonatooxy-5-(hydroxymethyl)oxolane-3,4-diol
2,4-Dichloro-6-[(E)-thiazol-2-yliminomethyl]-phenol
2-[(2,4-Dichlorophenyl)methylthio]-1-methylimidazole
C11H10Cl2N2S (271.99417200000005)
(7-Hydroxy-1-oxoisochromen-3-yl)methyl hydrogen sulate
6-(2,3-dichlorophenyl)-2-oxo-1H-1,2,4-triazin-2-ium-3,5-diamine
(Z)-4-(2-hydroxy-5-sulfo-phenyl)-2-oxo-but-3-enoic Acid
4-Hydroxy-2,4,6-trichlorobiphenyl
D004785 - Environmental Pollutants > D011078 - Polychlorinated Biphenyls
6,7-dichloro-L-tryptophan zwitterion
An L-alpha-amino acid zwitterion resulting from the transfer of a proton from the carboxy group to the alpha-amino group of 6,7-dichloro-L-tryptophan; major species at pH 7.3.
2-Methylcitric acid (trisodium)
2-Methylcitric acid trisodium (Methylcitric acid trisodium) is an endogenous metabolite in the 2-methylcitric acid cycle. 2-Methylcitric acid trisodium accumulates in methylmalonic and propionic acidemias and acts as a marker metabolite. 2-Methylcitric acid trisodium markedly inhibits ADP-stimulated and uncoupled respiration in mitochondria supported by glutamate[1].
(3e,5s,6r)-5,6-dichloro-2-(dichloromethyl)-6-methylocta-1,3,7-triene
5-bromo-6,8-dihydroxy-3-methyl-3,4-dihydro-2-benzopyran-1-one
3-[(5-bromopyridin-2-yl)-c-hydroxycarbonimidoyl]propanoic acid
C9H9BrN2O3 (271.97965039999997)
1-bromo-1,2-dichlorooct-1-en-3-one
C8H11BrCl2O (271.93702759999996)
7-bromo-6,8-dihydroxy-3-methyl-3,4-dihydro-2-benzopyran-1-one
5,6-dichloro-2-(dichloromethyl)-6-methylocta-1,3,7-triene
(3r)-7-bromo-6,8-dihydroxy-3-methyl-3,4-dihydro-2-benzopyran-1-one
(3e,5r,6r)-5,6-dichloro-2-(dichloromethyl)-6-methylocta-1,3,7-triene
(1z)-1-bromo-1,2-dichlorooct-1-en-3-one
C8H11BrCl2O (271.93702759999996)
(5r,6r)-5,6-dichloro-2-(dichloromethyl)-6-methylocta-1,3,7-triene
(3r)-5-bromo-6,8-dihydroxy-3-methyl-3,4-dihydro-2-benzopyran-1-one
4-chloro-2-(4-chloro-1h-pyrrol-3-yl)-3-nitrophenol
C10H6Cl2N2O3 (271.97554660000003)